epocrates
Manufacturer withdraws Tazverik from market after safety concerns emerge
Ipsen has voluntarily withdrawn Tazverik (tazemetostat) from all global markets following emerging safety concerns identified in the ongoing SYMPHONY‑1 trial (NCT04224493), which evaluated tazemetostat combined with lenalidomide plus rituximab (R2) in follicular lymphoma. The Independent Data Monitoring Committee advised that the regimen showed an unfavorable safety profile, including secondary hematologic malignancies, with risks outweighing potential benefits. As a result, Ipsen has halted all Tazverik treatment, discontinued active clinical trials and expanded access programs, and will transition enrolled patients to standard-of-care therapy.
Source:
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma [Press Release]. https://www.ipsen.com/press-release/ipsen-voluntarily-withdraws-tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-3251503/